Defining the clinical course of multiple sclerosisFred Lublin, Chris H. Polman, Stephen C. Reingold et al.|Neurology|2014Cited by 3.1k
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, Stephen L. Hauser, David Li et al.|The Lancet|2011Cited by 743
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysisAxel Petzold, Bernhard Hemmer, Laura J. Balcer et al.|The Lancet Neurology|2017Cited by 572
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelinationLeslie A. Kirby, Peter A. Calabresi|Nature Communications|2019Cited by 426